Kojic acid is legal for use in cosmetic body milk in both the US and EU, but the regulatory environments differ meaningfully and founders need to understand those differences before selecting a target market.
In the United States, the FDA does not impose a specific concentration cap on kojic acid in rinse-off or leave-on cosmetics, because it is regulated as a cosmetic ingredient rather than an over-the-counter drug (provided no drug claims are made). Most US-market formulators keep kojic acid at 0.5%–2% in body applications. The key compliance requirement is that claims must not cross into drug territory — statements like 'treats hyperpigmentation' or 'corrects melasma' can trigger OTC drug classification and FDA enforcement action. Acceptable claim language includes 'evens skin tone', 'visibly brightens', and 'reduces the appearance of dark spots'.
In the European Union, the SCCS (Scientific Committee on Consumer Safety) has issued opinions on kojic acid multiple times. The current position, as of the most recently adopted restriction under Regulation (EC) 1223/2009, restricts kojic acid to a maximum of 1% in face products. Body product applications remain under active scientific review. EU-compliant brands operating conservatively often cap kojic acid at 1% in body milk as a precautionary measure and ensure this is clearly documented in the Product Information File (PIF). Brands entering the EU market must appoint a Responsible Person established in the EU and maintain a full CPSR.
In the United Kingdom post-Brexit, kojic acid follows its own GB cosmetics regulations (essentially mirroring EU standards through retained law), and brands must maintain a UK-specific RP and PIF.
In Japan, kojic acid has a long-standing approval as a quasi-drug (医薬部外品) active for skin brightening at concentrations up to 1%, which gives it a legitimacy and market familiarity that is sometimes stronger than in Western markets. K-beauty and J-beauty manufacturers are experienced in formulating compliant brightening products for multiple regulatory zones simultaneously.
Transexamic acid (TXA) is far less regulated at cosmetic concentrations. It appears on no major restricted lists in the US, EU, or UK as of the time of writing, and is typically used at 2%–3% in cosmetic body milks without regulatory concern, provided drug claims are avoided.
The common mistake is launching a kojic acid product into the EU at 2% without a SCCS-compliant safety assessment. EU customs and market surveillance authorities do pull products, and a non-compliant product can be withdrawn from market at significant cost. Always commission a CPSR from a qualified EU toxicologist before EU launch.
Ingredients in this answer: Kojic Acid
Read the full guide on Private Label Tranexamic & Kojic Acid Body Milk Low MOQ →